CTI BioPharma
223 articles about CTI BioPharma
-
CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27
2/20/2019
CTI BioPharma Corp. announced that management will provide a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference at 11:30 a.m. EST at the Lotte New York Palace Hotel.
-
CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®
2/11/2019
CTI BioPharma Corp. announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd.
-
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
2/1/2019
CTI BioPharma Corp. announced that the Company will withdraw its European Marketing Authorization Application for pacritinib as a treatment for myelofibrosis.
-
CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development
12/18/2018
CTI receives input on key elements of new Phase 3 trial design for patients with myelofibrosis and severe thrombocytopenia
-
CTI BioPharma Announces Restructuring Plan
12/13/2018
Fifty percent reduction in workforce expected to improve efficiencies and preserve capital for pacritinib development
-
CTI BioPharma Reports Third Quarter 2018 Financial Results
11/1/2018
CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the third quarter and nine months ended September 30, 2018.
-
CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018
10/25/2018
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2018 financial results on Thursday, November 1, 2018,
-
CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review
10/1/2018
Trial to continue to full enrollment of all three treatment arms
-
CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3
9/26/2018
Management will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference at the InterContinental New York Barclay Hotel.
-
Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations
9/6/2018
Industry veteran to lead and execute operations for pivotal Phase 3 SIERRA trial for Iomab-B.
-
CTI BioPharma Reports Second Quarter 2018 Financial Results
8/2/2018
Management to Host Conference Call/Webcast Today at 4:30 p.m. Eastern Time
-
CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018
7/26/2018
CTI BioPharma Corp. announced that management plans to report its second quarter 2018 financial results on Thursday, August 2, 2018
-
CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA
7/18/2018
Regulatory path to include Phase 3 trial expected to begin in 2019
-
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
7/9/2018
PIXUVRI® plus rituximab did not show a statistically significant improvement in progression-free survival compared to gemcitabine plus rituximab
-
Shares of CTI BioPharma Corp. are down more than 15 percent in premarket trading this morning after the company announced its combination treatment for B-cell non-Hodgkin lymphoma failed to meet endpoints in a late-stage trial.
-
CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib
7/2/2018
The IDMC did not identify any drug- or dose-related safety concerns and specifically did not identify any concerns about cardiac or bleeding events.
-
CTI BioPharma to Present at the JMP Securities 2018 Life Sciences Conference
6/14/2018
CTI BioPharma Corp. announced that management will present at the JMP Securities 2018 Life Sciences Conference in New York
-
CTI BioPharma to Present at the Jefferies 2018 Global Healthcare Conference
6/6/2018
The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website
-
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
3/9/2018
Demonstrated a significant improvement of 35% or more in spleen volume reduction (SVR) at 24 weeks of treatment in 27 patients (18%).
-
CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results
3/7/2018
CTI BioPharma Inc. reported financial results for the fourth quarter and full year ended December 31, 2017.